Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors

Journal of Neuro-Oncology

Volumn 107, Issue 2, 2012, Pages 407-411

  Goldlust, Samuel A ^a,b   Cavaliere, Robert ^c   Newton, Herbert B ^c   Hsu, Meier ^d   DeAngelis, Lisa M ^a   Batchelor, Tracy T ^e   Gilbert, Mark R ^f   Lassman, Andrew B ^a,g  

^a Brain Tumor Center   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g Department of Medicine   (United States)

Author keywords

Bevacizumab; Glioblastoma; Glioma; Tyrosine kinase inhibitor; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CEDIRANIB; CORTICOSTEROID; ERLOTINIB; LOMUSTINE; SORAFENIB; SUNITINIB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SALVAGE THERAPY; SAMPLE SIZE; SURVIVAL TIME; TREATMENT OUTCOME; BRAIN; BRAIN TUMOR; DRUG ANTAGONISM; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84863600431     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0768-1     Document Type: Article

References (11)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
2. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745
3. Cloughesy T, Vredenburgh JJ, Day B, Das A, Friedman HS, for the BRAIN Investigators (2010) Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J Clin Oncol 28:15s (suppl; abstract 2008)
4. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972
5. Karnofsky DA, Abelmann WH, Carver LF, Burchenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer 1:634-656
6. Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, Duerinck J, Tynninen O, Nupponen N, Michotte A, De Greve J (2010) Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 103(3):491-501
7. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 12:855-861
8. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817-2823
9. Wen PY, Prados M, Schiff D, Reardon DA, Cloughesy T, Mikkelsen T, Batchelor T, Drappatz M, Chamberlain MC, De Groot JF (2010) Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). J Clin Oncol 28:15s (suppl; abstract 2006)
10. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY (2010) Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol 12:603-607
11. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK (2011) Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res 71:19-28